Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Children's Hospital Los Angeles
Children's Oncology Group
Novartis
National Cancer Institute (NCI)
New Approaches to Neuroblastoma Therapy Consortium
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Actuate Therapeutics Inc.
Columbia University
City of Hope Medical Center
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Pfizer
Hoffmann-La Roche
Children's Oncology Group
University of Birmingham
Children's Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
Rush University Medical Center
Columbia University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Children's Oncology Group
Duke University
Children's Oncology Group
Canadian Cancer Trials Group
Emory University
Baylor College of Medicine
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
St. Jude Children's Research Hospital
Case Comprehensive Cancer Center
University of Cologne
Centre Oscar Lambret
GlaxoSmithKline
Children's Oncology Group
Children's Oncology Group
Seoul National University Hospital
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)